183721-15-5
183721-15-5
Chemical Structure
MRS1220
- CAS No.: 183721-15-5
- Formula:C21H14ClN5O2
- Molecular Weight:403.82
IUPAC Name: N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide
InChIKey: TWWFAXQOKNBUCR-UHFFFAOYSA-N
SMILES: O=C(NC1=NC2=C(C=C(Cl)C=C2)C3=NC(C4=CC=CO4)=NN13)CC5=CC=CC=C5
Biological Activity: MRS1220, a highly potent and selective human A3 adenosine receptor (hA3AR) antagonist with a Ki of 0.59 nM, has therapeutic potential for the research of diseases of the central nervous system[1]. MRS1220 reduces glioblastoma tumor size and blood vessel formation in vivo[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MRS1220 | 99.52% | MRS1220, a highly potent and selective human A3 adenosine receptor (hA3AR) antagonist with a Ki of 0.59 nM, has therapeutic potential for the research of diseases of the central nervous system. MRS1220 reduces glioblastoma tumor size and blood vessel formation in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MRS1220 (Standard) | ≥98% | MRS1220 (Standard) is the analytical standard of MRS1220 (HY-103190). This product is intended for research and analytical applications. MRS1220, a highly potent and selective human A3 adenosine receptor (hA3AR) antagonist with a Ki of 0.59 nM, has therapeutic potential for the research of diseases of the central nervous system. MRS1220 reduces glioblastoma tumor size and blood vessel formation in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. K A Jacobson, et al. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology. 1997 Sep;36(9):1157-65. [Content Brief]
- [2]. René Rocha, et al. The Adenosine A₃ Receptor Regulates Differentiation of Glioblastoma Stem-Like Cells to Endothelial Cells under Hypoxia. Int J Mol Sci. 2018 Apr 18;19(4):1228. [Content Brief]
